Question for written answer E-000242/2024
to the Commission
Rule 138
Gianna Gancia (ID)

Subject: Evaluation of the administration of triptorelin in paediatrics for the treatment of gender dysphoria

Children's physical and mental health and well-being must be protected, especially in sensitive contexts such as gender transition pathways.

Triptorelin, a drug approved for veterinary use by the European Medicines Agency, is used to block the development of sex characteristics in adolescents with gender dysphoria. There are concerns about it being administered to children without proper psychotherapeutic and psychiatric care, and about the superficiality of pre-treatment psychological assessments. The Italian Ministry of Health has initiated an audit at Careggi Hospital in Florence to investigate those practices and is calling for the use of triptorelin to be reassessed.

In view of the above:

1. Does the Commission believe that the current paediatric administration practices for triptorelin conform to European regulations and guidelines on medical safety and ethics?

2. What view would it take of the possible publication of specific guidelines for the treatment of gender dysphoria in children, including strict criteria for psychological assessments and the administration of medication?

Submitted:25.1.2024